Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Receivables (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Receivables for 3 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 18.84% to $19.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.4 million, a 18.84% increase, with the full-year FY2025 number at $19.4 million, up 18.84% from a year prior.
  • Receivables was $19.4 million for Q4 2025 at Nuvation Bio, up from $13.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $19.4 million in Q4 2025 to a low of $3.7 million in Q4 2023.
  • A 3-year average of $9.2 million and a median of $6.1 million in 2025 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 340.09% in 2024, then grew 18.84% in 2025.
  • Nuvation Bio's Receivables stood at $3.7 million in 2023, then skyrocketed by 340.09% to $16.3 million in 2024, then increased by 18.84% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Receivables are $19.4 million (Q4 2025), $13.8 million (Q3 2025), and $6.7 million (Q2 2025).